CELLPHIRE, INC. - CRYOPRESERVED PLATELET (CPP) DEVELOPMENT FOR US FDA LICENSURE
Key Details
Description
CRYOPRESERVED PLATELET (CPP) DEVELOPMENT FOR US FDA LICENSURE
Context & Analysis
On Nov 25, 2025, Department of Defense obligated $59,971,856.1 to CELLPHIRE, INC. for cryopreserved platelet (cpp) development for us fda licensure. The award is classified under NAICS 541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY) and issued as a cost plus fixed fee contract. Competition extent: full and open competition after exclusion of sources with 3 offers received. The procurement used a SMALL BUSINESS SET ASIDE - TOTAL set-aside. Performance is located in ROCKVILLE, MD. The contract is scheduled through Oct 31, 2028. This award is one of several similar procurements from Department of Defense under NAICS 541715 — related awards are listed below.
Contractor Information
Similar Awards
NAVAL NUCLEAR LABORATORY
FLUOR MARINE PROPULSION, LLC
$14.2B
NAVAL NUCLEAR LABORATORY
FLUOR MARINE PROPULSION, LLC
$13.6B
NEXT GENERATION OVERHEAD PERSISTENT INFRARED GEOSYNCHRONOUS EARTH ORBIT SPACE VEHICLE 1-3 PHASE 1
LOCKHEED MARTIN CORP
$6.3B
NEXT GENERATION OVERHEAD PERSISTENT INFRARED GEOSYNCHRONOUS EARTH ORBIT SPACE VEHICLE 1-3 PHASE 1
LOCKHEED MARTIN CORP
$6.3B
DESIGN, DEVELOPMENT, AND DEVELOPMENTAL TESTING OF THE NEXT GENERATION INTERCEPTOR (NGI) ALL-UP-ROUND (AUR)
LOCKHEED MARTIN CORPORATION
$4.6B
Stay Updated
Get notified about new opportunities matching your interests.